**Full Clinical Recovery after Topical Acyclovir Treatment of Epstein-Barr Virus Associated Cutaneous B-Cell Lymphoma in Patient with Mycosis Fungoides**

M. Sitki Copur1,2, Anita Deshpande1, Kris Mleczko1, Max Norvell1, Gordon J. Hrnicek1, Suzette Woodward1, Scott Frankforter1, Natalie Mandolfo1, Kai Fu1, Wing C. Chan2

1Saint Francis Medical Center, Grand Island; and 2University of Nebraska Medical Center, Omaha, Neb, USA

**Abstract**

Primary cutaneous T- and B-cell lymphomas are a heterogeneous group of diseases with varied clinical presentations and prognosis. The use of new molecular, histological, and clinical criteria has improved their recognition. Cutaneous B-cell and T-cell lymphomas are seldom found together in the same patient. Here we report a rare case of mycosis fungoides variant of a cutaneous T-cell lymphoma (CTCL) which later developed Epstein-Barr virus (EBV) associated cutaneous B-cell lymphoproliferative disorder. The patient initially presented with generalized erythroderma, extensive plaques, and axillary lymphadenopathy. Histopathology and immunophenotyping of her tumor from the right breast nodule revealed a T-cell lymphoma consistent with mycosis fungoides. She was initially treated with pentostatin, followed by topical mechlorethamine and topical steroids. After progression of her mycosis fungoides with worsening diffuse skin lesions on this regimen, her treatments were changed to oral bexarotene with an initial partial response followed by stable disease. Three years from her initial presentation, she developed ulcerated cauliflower-like nodules on her forehead. Biopsy of these lesions revealed EBV-positive large- and medium-sized pleomorphic B-cells consistent with EBV-driven B-cell lymphoproliferative disorder. She was treated with topical acyclovir cream on the involved skin areas while continuing with oral bexarotene for mycosis fungoides. Skin lesions gradually diminished and totally disappeared after four weeks of topical acyclovir treatment. Bexarotene treatment was continued for another year until the mycosis fungoides progressed and became wide spread causing her death four and a half years after the initial diagnosis. The coexistence of two cutaneous non-Hodgkin lymphomas of different lineage in the same patient and the complete clinical response of EBV-related B-cell cutaneous component to topical acyclovir makes this rare case particularly interesting.

Primary cutaneous B- and T-cell lymphomas have been recognized as a heterogeneous group of cutaneous non-Hodgkin lymphomas with distinct variability in clinical presentation, histopathology, immunophenotype, genetic abnormalities, and prognosis (1). Primary cutaneous T-cell lymphomas (CTCL) comprise a constellation of heterogeneous lymphoproliferative disorders characterized by clonal accumulation of neoplastic T lymphocytes in the skin. Mycosis fungoides is the most frequent variant of CTCL, clinically characterized by the development of patches, plaques, or tumors. Primary cutaneous B-cell lymphomas are lymphoid neoplasms arising within the skin without evidence of systemic involvement (2). The etiology of both T-cell and B-cell cutaneous lympho-
mas is largely unknown. Viral infectious etiologies, including human T-lymphocyte virus-1 (HTLV-1), human herpes virus-8 (HHV-8), herpes simplex virus (HSV), hepatitis C virus, and Epstein-Barr Virus have been proposed as causative factors. However, none of these entities has been conclusively associated with either primary cutaneous T-cell or B-cell lymphomas (3-6). There have been occasional reports of CTCL associated with B-cell lymphoproliferative disorders, including plasma cell dyscrasia, chronic lymphocytic leukemia (CLL), and B-cell lymphomas (7-9). The coexistence of T- and B-cell cutaneous lymphoma in the same patient, however, is very rare. Here we report a case of Epstein-Barr virus (EBV) related B-cell cutaneous lymphoproliferative disorder (LPD) in a patient with CTCL wherein the B-cell LPD had a complete clinical response to topical acyclovir treatment.

Case Report

A 61-year-old white female was seen for extensive skin rash, axillary lymphadenopathy, and a palpable mass on her right breast. She gave a year history of pruritic erythematous, scaling lesions of her skin, mostly on her trunk and scalp. She had been treated with topical steroids, with minor improvement. Her skin lesions gradually spread to involve her entire body, with diffuse thickening of the skin, generalized erythroderma, and leonine face (Fig. 1). Prior to the referral, she had also noticed a nodule under the skin of her right breast. Physical examination revealed a number of large erythematous scaling patches on her chest, back, arms, thighs, legs, and face, covering almost 70% of her body. There were bilateral axillary lymph nodes 2-3 cm in size and a palpable 2 cm nodule on the lateral part of her right breast. Physical exam was negative for other sites of lymphadenopathy or hepatosplenomegaly.

Laboratory and Imaging Studies

White blood cells count was 6,900/µL (61% neutrophils, 32% lymphocytes, 7% monocytes), hemoglobin 14.5 g/dL, hematocrit 46%, and the platelet count was 298,000/µL. Hepatic and renal function panels were normal. The lactate dehydrogenase level was slightly elevated, at 235 IU/L (normal: 20-200 IU/L). Antinuclear antibody screen was negative. No antibodies were detected to human immunodeficiency virus-1 (HIV-1) or HTLV-1. The titers of anti EBV antibodies were as follows: anti-viral capsid antigen IgG >2 enzyme immuno assay (EIA) value (normal <0.9) and anti-nuclear antigen IgG >5 EIA value (normal <0.9). Peripheral blood flow cytometry analysis was negative for phenotypically abnormal cell populations. Mammography revealed a 1.8×2.2 cm mass located laterally corresponding to the palpable abnormality on her physical exam. Computerized tomography scans of the neck, chest, abdomen, and pelvis confirmed bilateral axillary lymphadenopathy but no other sites of lymphoma involvement.

Stereotactic breast biopsy revealed a lymph node with a cytologic and architectural abnormality suspicious for lymphoma (Fig. 2). Polymerase chain reaction (PCR) analysis for T-cell receptor gamma gene rearrangements showed a clonal T-cell process. Further skin biopsy confirmed the diagnosis of mycosis fungoides.

Treatment and Clinical Course

The patient was initially treated with 2’-deoxycoformycin (pentostatin), 4 mg/m²/week for the first 4 weeks and then every 2 weeks until maximal response. After a total of 12 treatments, she had a more than 50% improvement in her skin lesions and her axillary lymphadenopathy resolved. Treatments were changed to topical corticosteroids and topical mechlorethamine (nitrogen mustard, HN₂) which kept her disease under control for almost a year. When she had progressive worsening of the skin lesions and developed allergic reactions to nitrogen mustard, a year after her initial diagnosis, she was given oral bexarotene at a dose of 300 mg/m². She had an initial partial response followed by stable disease for two years.
Three years from the initial presentation, she developed fungating, ulcerated, cauliflower-like nodular lesions on her forehead (Fig. 3). The biopsy of these lesions revealed large and medium-sized pleomorphic B-cells (Fig. 4) consistent with diffuse large B-cell lymphoma of the skin. There was a partial loss of CD20 expression and a predominance of κ light chain expression with a marked increase in λ to κ ratio, consistent with the presence of a monoclonal B-cell proliferation. These B cells were EBV-positive by in situ hybridization for Epstein-Barr virus Encoded RNA (EBER) (Fig. 5). There was no demonstrable clonal T-cell receptor gene rearrangement in this lesion. These new skin lesions were treated with topical 5% acyclovir ointment six times daily while she continued taking oral bexarotene. These nodular skin lesions on her forehead gradually diminished in size and totally disappeared after four weeks of topical acyclovir treatment (Fig. 3). She continued with oral bexarotene for another year, when mycosis fungoides progressed with wide spread visceral involvement, causing her death four and a half years after the initial diagnosis.

Discussion

Primary cutaneous lymphomas are the second most common group of extranodal non-Hodgkin lymphomas (1). The final diagnosis in cutaneous lymphoma is based on clinical, histopathologic, immunophenotypic, and molecular criteria. Only 20-25% of cutaneous lymphomas are of B-cell origin, whereas as much as 60-65% are CTCLs (1-2). There are several reports of coexistent cutaneous T-cell lymphomas and B-cell malignancies (7-9). In a review of 19 such cases, 5 had
CTCL preceding the B-cell malignancy, and in another 5 the exact sequence was not clear. The most common B-cell malignancy was CLL (9 cases) (10). The coexistence of two cutaneous non-Hodgkin lymphomas of different lineage is rare. Hull et al (11) reported an 84 year old male patient with mycosis fungoides who later developed chronic lymphocytic leukemia that presented in the skin (leukemia cutis). Kikuchi et al (12) described a patient with long standing erythrodermic cutaneous T-cell lymphoma who developed an EBV-related systemic B-cell lymphoma that spread to involve the skin.

Our patient presented with diffuse erythroderma, skin nodules, and axillary lymphadenopathy without visceral involvement, putting her in the intermediate prognosis group for CTCL (13). After an initial response and stabilization of her CTCL with appropriate treatment, she developed a concurrent EBV-related cutaneous B-cell lymphoma on the skin of her forehead, with no evidence of systemic B-cell lymphoma. Although her EBV-associated B-cell cutaneous lymphoma responded completely to topical acyclovir, the CTCL eventually progressed and caused her death.

Viral infections can be responsible for lymphoproliferative disorders, as illustrated by EBV in endemic Burkitt lymphoma and HTLV-1 in adult T-cell lymphoma leukemia. Additionally, immunosuppressed patients are at risk for EBV induced B-cell lymphoproliferative disorder (LPD) such as post-transplant lymphoproliferative disease (14). Although rare, EBV-related primary cutaneous B-cell LPDs have been reported in several immunocompromised patients (15-17). Lymphoproliferative disorders are more likely to occur in patients with a family history of CTCL and a higher second malignancy risk has been reported in patients with CTCL (18,19). Cytokines are produced by the neoplastic helper/inducer T-lymphocytes in CTCL, as well as normal T-cells. Some of these may promote B-cell growth and subsequent development of a malignant B-cell clone (20-23). Furthermore, an impaired T-cell response caused by CTCL and/or intermittent chemotherapy may permit an uninhibited growth of EBV-transformed B-cells (24,25), leading eventually to a cutaneous B-cell lymphoma.

EBV-related post-transplant lymphoproliferative disorders have been successfully treated by reducing immunosuppression and initiating administration of acyclovir (15,26,27). Acyclovir inhibits continued B-cell proliferation by interrupting EBV replication. Similarly, gancyclovir and...
foscmarnet are powerful inhibitors of herpesviruses including EBV, but are not available in topical form. Because of the availability, ease of use, and lack of toxicity, we tried topical acyclovir in our patient. Full clinical response to topical acyclovir confirmed the causative role of EBV.

References


Correspondence to:
M. Sitki Copur
Saint Francis Cancer Center
2116 W Faidley Ave
Grand Island, NE 68802-9804, USA
mcopur@sfmc-gi.org